Inotersen (Tegsedi®) is indicated for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/08/2019|
|Rapid review completed||07/10/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inotersen compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||09/10/2019|
|Pre-submission consultation with Applicant||08/12/2020|
|Full HTA submission received from Applicant||23/07/2021|
|Preliminary review sent to Applicant||05/10/2021|
|NCPE assessment re-commenced||02/11/2021|
|Factual accuracy check sent to Applicant||22/12/2021|
|NCPE assessment re-commenced||10/01/2022|
|NCPE assessment completed||11/02/2022|
|NCPE assessment outcome||The NCPE recommends that inotersen be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.